Unified global action needed to tackle bedaquiline-resistant tuberculosis

There has been remarkable recent transformation in the treatment of people with rifampicin-resistant and multidrug-resistant tuberculosis (RR/MDR-TB). On the basis of high-quality evidence, a majority of individuals with RR/MDR-TB can now be treated with WHO-recommended, all-oral regimens.¹ These recommended regimens all contain the diarylquinoline drug bedaquiline…

Please email sshiftb@gmail.com for a copy of the full article